Anatomic Pathology Market
The increase in the prevalence of cancer and kidney diseases and the rise in the number of strategic initiatives are contributing to the anatomic pathology market growth. However, the shortage of skilled professionals and stringent government regulations hamper the market growth. Further, the integration of artificial intelligence and machine learning is expected to bring new anatomic pathology market trends in the coming years.
Integration of Artificial Intelligence and Machine Learning to Bring New Trends in Anatomic Pathology Market During Forecast Period
Digital pathology, a growing subfield within anatomical pathology, uses digital technologies to streamline data collection and management. It helps reduce risks to specimen samples and has the potential to accelerate enrolment in clinical trials. Additionally, digital pathology can decrease sample-to-result turnaround time and streamline the central pathology review process, offering opportunities to increase trial efficiency.
To introduce upgraded technologies, machine learning (ML) and artificial intelligence (AI) are integrated with digital pathology for proper analysis and management of data. Several anatomic pathology laboratories are becoming increasingly aware of the benefits of digitization and AI in practice. Moreover, recent technological advancements and regulatory approvals are encouraging the digitalization of laboratory operations to improve the speed and accuracy of processes. With AI and ML, pathologists will have an augmented ability to improve diagnostic accuracy, efficiency, and consistency.
In November 2023, Dedalus Group and Ibex Medical Analytics launched a fully integrated End-to-End AI-powered Digital Pathology Solution for cancer diagnostics. It enables complete digitization of anatomic pathology labs with a next-generation Anatomic Pathology Information System (AIS) and DP solution, harnessing the power of data and AI for assisted case prioritization, advanced image analysis, and reproducible diagnoses. The rising focus on integrating AI technology for anatomical pathology processes due to its benefits is expected to fuel the growth of the market during the forecast period.
The geographic scope of the anatomic pathology market report covers North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa). In the US, cancer has a significant impact on society. A few common cancer types in the country are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, and liver cancer. As per the National Cancer Institute, in 2021, ~17.43 individuals had cancer at any site in the US. The number of cancer survivors is projected to reach 22.2 million by 2030. This mounting prevalence of cancer cases is expected to increase the demand for pathologic diagnostic tests such as biopsies, fine-needle aspiration (FNA), genetic testing, and other novel techniques. Moreover, there has been unprecedented growth in innovative and improved medical technologies in the US in recent years. This growth resulted in the development of advanced medical devices in the healthcare industry. Players operating in the US anatomic pathology market continuously focus on the development of innovative and convenient instruments and consumables for pathological procedures. In November 2023, Illumina Inc., US, a global leader in DNA sequencing and array-based technologies, introduced TruSight Oncology 500 ctDNA v2 (plate number 1 ctDNA v2), a new version of its distributed liquid biopsy assay that allows comprehensive noninvasive genomic profiling of circulating tumor DNA from blood, complementing tissue-based testing. In 2020, F. Hoffmann-La Roche received the US Food and Drug Administration (FDA) approval for the expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer. Thus, factors such as the high prevalence of cancer, the strong presence of a few major players, and the availability of high-quality infrastructure for hospitals and clinical laboratories bolster the growth of the anatomic pathology market in the US. There is a growing emphasis on early disease diagnosis among the Canadian population. Various companies and research organizations are engaged in raising awareness about the importance of early detection of cancers and other chronic diseases. These trends in the market are projected to drive the anatomic pathology market in the country. Adela, a Toronto-based spinout company from Canada’s University Health Network, closed a US$ 60 million Series A financing round led by F-Prime Capital for its licensed cell-free methylated DNA-based liquid biopsy technology that may have applications in various cancer tests, particularly to facilitate the early detection of cancer. Therefore, the surging adoption of novel anatomic pathological tests, coupled with product innovations, drives the growth of the anatomic pathology market in Canada.
The anatomic pathology market analysis has been carried out by considering the following segments: products and services, application, end user, and geography. Based on products and services, the anatomic pathology market is segmented into instruments, consumables, and services. The services segment is further bifurcated into histopathology and cytopathology. The instruments segment is further divided into microtomes and cryostat, automatic stainers, tissue processors, and others. By application, the market is segmented into disease diagnosis, drug discovery and development, and others. Based on end user, the anatomic pathology market is divided into hospitals, research laboratories, diagnostic laboratories, and others.
Anatomic Pathology Market: Competitive Landscape and Key Developments
F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, BD, and PHC Holdings Corporation are among the prominent players profiled in the anatomic pathology market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem. These companies focus on geographic expansions and new product launches to meet the increasing demand from consumers worldwide and diversify their product range in specialty portfolios. Their global presence allows them to serve a large customer base, subsequently facilitating market expansion.
